缬沙坦/氢氯噻嗪治疗轻、中度原发性高血压患者疗效和安全性

摘要

目的：评价缬沙坦/氢氯噻嗪治疗经单用缬沙坦控制不良的轻、中度原发性高血压患者疗效和安全性。方法：选择我院收治的100例经单用缬沙坦控制不良的轻、中度原发性高血压患者的临床资料，其中，观察组患者50例采用缬沙坦/氢氯噻嗪进行治疗，而对照组50例患者采用缬沙坦进行治疗，比较两组患者治疗的有效性和安全性。结果：治疗后，观察组患者的总有效率为92.00%，明显高于对照组患者，且差异具有明显统计学意义(P<0.05)，而且，观察组患者的收缩压和舒张压的改善程度均明显优于对照组患者(P<0.05)。结论：采用缬沙坦/氢氯噻嗪复方制剂治疗轻、中度原发性高血压患者具有十分显著的疗效，其安全可靠，无明显不良反应发生，值得临床广泛推广和应用。%Objective:To evaluate the efficacy and safety of valsartan/Hydrochloroth-Iazide in treatment of mild to moderate essential hypertension.Methods:100 cases in our hospital with mild to moderate essential hypertension were divided into two groups,including the observation group of 50 patients were treated with valsartan/hydrochlorothiazide treatment,while the control group of 50 patients were treated with valsartan treatment,and the efficacy and safety of two groups were compared. Results:After treatment,the group of patients with total effective rate 92.00%,significantly higher than the patient,and the difference was statistically significant (P<0.05),but also to observe the group of patients with systolic and diastolic improvement patients were significantly better than the control group (P<0.05).Conclusion:Valsartan/Hydrochlorothiazide in treatment of mild to moderate essential hypertension has a very significant effect,and it is worthy of clinical and applied widely.